Mati­nas Bio shares are crushed on dis­ap­point­ing PhII an­ti­fun­gal da­ta

Shares of Mati­nas Bio­Phar­ma $MTNB were shred­ded ear­ly Mon­day af­ter the biotech an­nounced that its lead an­ti-in­fec­tives pro­gram failed to match a main­stay in the field in a mid-stage study.

MAT2203 hit the pri­ma­ry end­point on safe­ty and tol­er­a­bil­i­ty, but the biotech’s ex­ecs say they were dis­ap­point­ed that the ther­a­py failed to per­form as well as flu­cona­zole in treat­ing vul­vo­vagi­nal can­didi­a­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER